IRIS
CENTANNI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 52
AS - Asia 34
EU - Europa 30
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 119
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 51
SG - Singapore 31
IT - Italia 23
GB - Regno Unito 4
BR - Brasile 2
DE - Germania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
HK - Hong Kong 1
MX - Messico 1
NL - Olanda 1
PK - Pakistan 1
Totale 119
Salva come PNG Salva come JPEG
Città #
Singapore 18
Santa Clara 11
Milan 8
New York 4
Chicago 3
Lawrence 3
Muggiò 3
Princeton 3
Rome 3
Assago 2
Campobasso 2
Des Moines 2
London 2
Munich 2
Palermo 2
San Nicola Manfredi 2
Brooklyn 1
Charlotte 1
Cincinnati 1
Corpus Christi 1
Dubai 1
Harrisburg 1
Hong Kong 1
Itanhém 1
Legnago 1
Mexico City 1
Philadelphia 1
Phoenix 1
Preston 1
Rhyl 1
San Francisco 1
São Pedro 1
The Dalles 1
Wilmington 1
Totale 88
Salva come PNG Salva come JPEG
Nome #
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 18
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis 16
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study 14
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study 13
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? 12
Point-of-Care Lung Sonography: An Audit of 1150 Examinations 11
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study 10
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis 10
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 9
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study 8
Lung Ultrasound B Lines: Etiologies and Evolution with Age 8
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 3
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study 2
Totale 134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.976
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.976
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 2 0 0 0 0 0 0 0 0 0 0
2021/20228 0 0 0 0 0 0 2 2 0 1 3 0
2022/202310 6 0 0 1 1 1 0 1 0 0 0 0
2023/202425 5 1 3 0 0 5 1 2 0 3 5 0
2024/202588 16 2 3 1 2 13 14 5 1 2 17 12
Totale 134